In vitro activity of ramoplanin and comparator drugs against anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora

Finegold, Sydney M.; John, Shahera St.; Vu, A.; Li, Calida M; Molitoris, Denise; Song, Yuanyuan; Liu, Chengxu; Wexler, Hannah M.

doi:10.1016/j.anaerobe.2004.04.003

Cited by 22 publications

(10 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Susceptibilities for the comparator agents were typical for what has been reported in other surveys of anaerobic intestinal organisms (4,5,12,13,11). C. difficile resistance to cefoxitin, imipenem, clindamycin, and moxifloxacin was present in 100, 18, 66, and 26% of our isolates, respectively, while elevated MICs of 4 g/ml were found in two strains for vancomycin and in one for metronidazole.…”

supporting

confidence: 53%

See 1 more Smart Citation

Comparative In Vitro Activities of LFF571 against Clostridium difficile and 630 Other Intestinal Strains of Aerobic and Anaerobic Bacteria

Citron¹,

Tyrrell²,

Merriam³

et al. 2012

Antimicrob Agents Chemother

View full text Add to dashboard Cite

ABSTRACTThein vitroactivities of LFF571, a novel analog of GE2270A that inhibits bacterial growth by binding with high affinity for protein synthesis elongation factor Tu, fidaxomicin, and 10 other antimicrobial agents were determined against 50 strains ofClostridium difficileand 630 other anaerobic and aerobic organisms of intestinal origin. LFF571 possesses potent activity againstC. difficileand most other Gram-positive anaerobes (MIC90, ≤0.25 μg/ml), with the exception of bifidobacteria and lactobacilli. The MIC90s for aerobes, including enterococci,Staphylococcus aureus(as well as methicillin-resistantS. aureus[MRSA] isolates),Streptococcus pyogenes, and other streptococci were 0.06, 0.125, 2, and 8 μg/ml, respectively. Comparatively, fidaxomicin showed variable activity against Gram-positive organisms: MIC90s againstC. difficile,Clostridium perfringens, andBifidobacteriumspp. were 0.5, ≤0.015, and 0.125 μg/ml, respectively, but >32 μg/ml againstClostridium ramosumandClostridium innocuum. MIC90forS. pyogenesand other streptococci was 16 and >32 μg/ml, respectively. LFF571 and fidaxomicin were generally less active against Gram-negative anaerobes.

show abstract

supporting

confidence: 53%

“…a Anaerobic organisms were tested by the agar dilution method; aerobic organisms were tested by broth microdilution (7,8). e Peptostreptococcus anaerobius (12), P. stomatis (8).…”

Section: Methodsmentioning

confidence: 99%

Comparative In Vitro Activities of LFF571 against Clostridium difficile and 630 Other Intestinal Strains of Aerobic and Anaerobic Bacteria

Citron¹,

Tyrrell²,

Merriam³

et al. 2012

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

“…It has been demonstrated that vancomycin can alter the stool microbiota, and thus, decreases in diversity and richness prior to FT may be in part due to lingering effects of vancomycin as opposed to CDI per se (41). For example, it has been shown that vancomycin has activity against Bacteroidetes (42). Nevertheless, we observe the same paucity of Bacteroidetes and overexpansion of Proteobacteria seen by other studies of the CDI disease state in the absence of prior therapy with vancomycin (18, 43).…”

Section: Discussionmentioning

confidence: 99%

Toward an Understanding of Changes in Diversity Associated with Fecal Microbiome Transplantation Based on 16S rRNA Gene Deep Sequencing

Shahinas

Silverman

Sittler

et al. 2012

mBio

169

125

View full text Add to dashboard Cite

Fecal microbiome transplantation by low-volume enema is an effective, safe, and inexpensive alternative to antibiotic therapy for patients with chronic relapsing Clostridium difficile infection (CDI). We explored the microbial diversity of pre- and posttransplant stool specimens from CDI patients (n = 6) using deep sequencing of the 16S rRNA gene. While interindividual variability in microbiota change occurs with fecal transplantation and vancomycin exposure, in this pilot study we note that clinical cure of CDI is associated with an increase in diversity and richness. Genus- and species-level analysis may reveal a cocktail of microorganisms or products thereof that will ultimately be used as a probiotic to treat CDI.

show abstract

“…Ampicylina była słabo aktywna w stosunku do Gram-ujemnych laseczek Clostridium bolteae i C. clostridiforme. Metronidazol okazał się wysoce aktywnym antybiotykiem w stosunku do wszystkich grup badanych mikroorganizmów jelitowych, z wyjątkiem rodzaju Bifidobacterium [19].…”

Section: Czynniki Wpływające Na Układ Zespołu Mikroorganizmów Jelitowychunclassified

Gut microorganisms and their metabolic activity

Mroczyńska¹,

Libudzisz²,

Gałęcka³

et al. 2011

View full text Add to dashboard Cite

In vitro activity of ramoplanin and comparator drugs against anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora

Cited by 22 publications

References 18 publications

Comparative In Vitro Activities of LFF571 against Clostridium difficile and 630 Other Intestinal Strains of Aerobic and Anaerobic Bacteria

Comparative In Vitro Activities of LFF571 against Clostridium difficile and 630 Other Intestinal Strains of Aerobic and Anaerobic Bacteria

Toward an Understanding of Changes in Diversity Associated with Fecal Microbiome Transplantation Based on 16S rRNA Gene Deep Sequencing

Gut microorganisms and their metabolic activity

Contact Info

Product

Resources

About